A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers
Alberto D. Guerra(Children's Hospital of Philadelphia), Yaël P. Mossé(Children's Hospital of Philadelphia)
Cited by 3
Related Papers
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
|Nature Medicine|2023|125
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
|Clinical Cancer Research|2018|88
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
|Cancer Research|2021|70
An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma
|Science Translational Medicine|2019|68